ClinicalTrials.gg
RecruitingNCT04296370Updated Aug 10, 2020

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

A Phase 3 interventional study of Fluzoparib; Apatinib and Fluzoparib in Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2022, 4 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing fluzoparib in Breast Neoplasms — 11 open to participants now, 12 under way, 4 of them phase 3. fluzoparib · Breast Neoplasms.

Planned enrollment
4th of 15
474 · median 260
Started
2020
with 1 other
Phase 3
4 of 15
3 open now
Primary completion
2022-06
later than 0 of 11 live
Registered
1st of 15
by date
Lead sponsor
1 of 15
Jiangsu HengRui Medicine Co., Ltd.

Among the 15 studies testing fluzoparib in Breast Neoplasms, this one is the 4th largest by planned enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 15 studies testing fluzoparib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About fluzoparib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing fluzoparib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Physicians Choice Chemotherapy, as treatment, in patients with a Germline BRCA Mutation and HER2-negative Metastatic Breast Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.

03

Conditions studied

  • Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Saftey Lead-in + phase 3)Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious
  • (Saftey Lead-in + phase 3)human epidermal growth factor receptor type 2 ()-negative breast cancer
  • (Saftey Lead-in + phase 3)had received ≤2 for mBC
  • (Saftey Lead-in + phase 3)Prior therapy with an anthracycline and a taxane in either an or metastatic setting.
  • ER/PR breast cancer positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
  • performance status 0-1.
  • Adequate bone marrow, kidney and liver function.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib
  • Prior unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, DCIS or stage I grade 1 endometrial cancer allowed
  • Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization
  • Known to be positive
  • Known active virus, or known active virus
  • Untreated and/or uncontrolled
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
474 participants (estimated)

Study arms

  • Experimental
    Safety Lead-in, Doublet Arm

    Fluzoparib+Apatinib

    Drug: Fluzoparib; Apatinib

  • Experimental
    Single Arm

    Fluzoparib

    Drug: Fluzoparib

  • Active comparator
    Physician's choice chemotherapy

    Capecitabine or Vinorelbine

    Drug: Physician's choice chemotherapy

Interventions

  • DrugFluzoparib; Apatinib

    Drug pages: Fluzoparib · Apatinib

    Fluzoparib Orally twice daily; Apatinib Orally once daily

  • Fluzoparib Orally twice daily

  • DrugPhysician's choice chemotherapy

    Investigators will declare one of the following regimens: Capecitabine Vinorelbine

06

What researchers measure

Primary outcomes

  1. (Safety Lead-in) dose limited toxicity (DLT)

    dose limited toxicity (DLT) of Fluzoparib+Apatinib in the first cycle

    Time frame: up to 21 days

  2. (Safety Lead-in) Recommended Phase II Dose (RP2D)

    Recommended Phase II Dose (RP2D) of Fluzoparib+Apatinib

    Time frame: up to 21 days

  3. (Phase 3) Progression free survival(PFS) in HER2-negative Metastatic Breast Cancer patients

    Defined as progression free survival per RECIST 1.1 criteria according to BIRC criteria

    Time frame: Radiological scans performed at baseline then every ~6 weeks up to 30 weeks, then every ~ 9 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months

Secondary outcomes

  1. AEs+SAEs

    Adverse Events and Serious Adverse Events

    Time frame: from the first drug administration to within 30 days for the last treatment dose

  2. PFS by investigator's assessment

    Progression-Free-Survival

    Time frame: up to 30 months

  3. OS

    OS is the time interval from the start of treatment to death due to any reason or lost of follow-up

    Time frame: up to 30 months

  4. Patient Reported Outcomes (PROs) assessed by EORTC QLQ C30 questionnaire

    Comparison of the Quality of Life in study arms assessed by EORTC QLQ C30 questionnaire

    Time frame: up to 30 months

  5. Time to progression on the next anticancer therapy (PFS2)

    From date of start of next anticancer therapy to date of first documented progression of date of death from any cause, whichever comes first

    Time frame: up to 30 months

  6. Objective Response Rate (ORR)

    Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by CT or MRI

    Time frame: up to 30 months

  7. Disease control rate (DCR)

    Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1

    Time frame: up to 30 months

  8. Duration of response (DoR)

    Time from documentation of tumor response to disease progression assessed among patients who had an objective response

    Time frame: up to 30 months

07

Study locations

1 of 1 sites recruiting
  • Jiangsu HengRui Medicine Co., Ltd.
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jun 2022, 23 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2020
First posted
Mar 5, 2020
StartActual
Jul 13, 2020
Primary completionEst.
Jun 30, 2022
CompletionEst.
Jun 30, 2025
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04296370
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Jul 13, 2020
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Aug 10, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluzoparib · Apatinib

Start the discussion